Benefit of tianeptine and morphine in a transgenic model of familial amyotrophic lateral sclerosis

References

• Deng H. X., Hentati A., Tainer J. A., Iqbal Z., Cayabyab A., Hung W. Y., et al. Amyotrophic lateral sclerosis and structural defects in Cu/Zn superoxide dismutase. Science 1993; 261:1047–50
   Google Scholar
• Rosen D. R., Siddique T., Patterson D., Figlewicz D. A., Sapp P., Hentati A., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59–62
   PubMed Web of Science ®Google Scholar
• Price D. L., Wong P. C., Becher M. W., et al. Familial amyotrophic lateral sclerosis and transgenic models. Neurosci News 1998; 1: 21–7
   Google Scholar
• Gurney M. E., Pu H., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., Caliendo J., et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772–5
   PubMed Web of Science ®Google Scholar
• Dal Canto M. C., Gurney M. E. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu/Zn SOD, and in mice overexpressing wild‐type human SOD: a model of familial lateral sclerosis. Brain Res 199; 676: 25–40
   Google Scholar
• Puig S., Rivot J. P., Besson J. M. Effects of tianeptine on 5‐hydroxyindoles and on the morphine‐induced increase in 5‐HT metabolism at the medullary dorsal horn level as measured by in vivo voltametry in freely moving rats. Brain Res 1993; 600: 219–24
   PubMed Web of Science ®Google Scholar
• Aanonsen L. M., Wilcox G. L. Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists. J.Pharmacol Exp Ther 1987; 243: 9–19
   PubMed Web of Science ®Google Scholar
• Wilde M. I., Benfield P. Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 1995; 49: 411–39
   PubMed Web of Science ®Google Scholar
• Fattaccini C. M., Bolanos‐Jimenez F., Gozlan H., Hamon M. Tianeptine stimulates uptake of 5‐hydroxytryptamine in vivo in the rat brain. Neuropharmacology 1990; 29: 1–8
   PubMed Web of Science ®Google Scholar
• Ortiz J., Mocaer E., Artigas F. Effects of the antidepressant drug tianeptine on plasma and platelet serotonin concentrations in the rat. Eur J Pharmacol 1991; 199: 335–9
   PubMed Web of Science ®Google Scholar
• Chamba G., Lemoine P., Flachaire E., Ferry N., Quincy C., Sassard J., et al. Increased serotonin platelet uptake after tianeptine administration in depressed patients. Biol Psychiat 1991; 30: 609–17
   PubMed Web of Science ®Google Scholar
• Frankfurt M., McKittrick C. R., McEwen B. S., Luine V. N. Tianeptine treatment induces regionally specific changes in monoamines. Brain Res 1995; 696: 1–6
   PubMed Web of Science ®Google Scholar
• Kato G., Weitch A. F. Neurochemical profile of tianeptine, a new antidepressant drug. Clin Neuropharmacol 1988; 11: 43–50
   Web of Science ®Google Scholar
• Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–591
   PubMed Web of Science ®Google Scholar
• Lacomblez L., Bensimon G., Leigh P. N., Meininger V. Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group II. Lancet 1996; 347: 1425–31
   PubMed Web of Science ®Google Scholar
• Chritin M., Besson G., Mallaret M., Savasta M. Sclérose latérale amyotrophique et modèles animaux. Rev Neurol 2001; 157: 1351–61
   PubMedGoogle Scholar
• Bruijn L. I., Cleveland D. W. Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol 1996; 22: 373–87
   PubMed Web of Science ®Google Scholar
• Tu P. H., Gurney M. E., Julien J. P., Lee V. M., Trojanowski J. Q., et al. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor disease. Lab Invest 1997; 76: 441–5
   PubMed Web of Science ®Google Scholar
• Gurney M. E., Cutting F. B., Zhai P., et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial lateral sclerosis. Ann Neurol 1996; 39: 147–57
   PubMed Web of Science ®Google Scholar
• Gurney M. E., Fleck T. J., Himes C. S., Hall E. D. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998; 50: 62–6
   PubMed Web of Science ®Google Scholar
• Hottinger A. F., Fine E. G., Gurney M. E., Zurn A. D., Aebischer P., et al. The copper chelator d‐penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci 1997; 9: 1548–51
   PubMed Web of Science ®Google Scholar
• Nagano S., Ogawa Y., Yanagihara T., Sakoda S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett 1999; 265: 159–62
   PubMed Web of Science ®Google Scholar
• Barneoud P., Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 1999; 155: 243–51
   PubMed Web of Science ®Google Scholar
• Benoit E., Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch 1991; 419: 603–9
   PubMed Web of Science ®Google Scholar
• Martin D., Thompson M. A., Nadler J. V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250: 473–6
   PubMed Web of Science ®Google Scholar
• Hebert T., Drapeau P., Pradier L., Dunn R. J. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994; 45: 1055–60
   PubMed Web of Science ®Google Scholar
• Malgouris C., Daniel M., Doble A. Neuroprotective effects of riluzole on N‐methyl‐D‐aspartate‐ or veratridine‐induced neurotoxicity in rat hippocampal slices. Neurosci Lett 1994; 177: 95–9
   PubMed Web of Science ®Google Scholar
• Uzbay I. T., Cinar M. G., Aytemir M., Tuglular I. Analgesic effect of tianeptine in mice. Life Sci 1999; 64: 1313–9
   PubMed Web of Science ®Google Scholar
• Bowker R. M., Westlund K. N., Sullivan M. C., Coutler J. D. Organization of descending serotoninergic projections to the spinal cord. Prog Brain Res 1982; 57: 239–98
   PubMed Web of Science ®Google Scholar
• Marlier L., Teilhac J. R., Cerruti C., Privat A. Autoradiographic mapping of 5‐HT1, 5‐HT1A, 5‐HT1B and 5‐HT2 receptors in the rat spinal cord. Brain Res 1991; 550: 15–23
   PubMed Web of Science ®Google Scholar
• Dziedzicka‐Wasylewska M., Rogoz Z., Skuza G., Dlaboga D., Maj J., et al. Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D2/D3 receptors. Behav Pharmacol 2002; 13: 127–38
   PubMed Web of Science ®Google Scholar
• Chen L., Huang L. ‐. Y. M. Sustained potentiation of NMDA receptor‐mediated glutamate response through activation of protein kinase C by a µ opioid. Neuron 1991; 7: 319–26
   PubMed Web of Science ®Google Scholar
• Elmer G. I., Evans J. L., Ladenheim B., Epstein C. J., Cadet J. L., et al. Transgenic superoxide dismutase mice differ in opioid‐induced analgesia. Eur J Pharmacol 1995; 283: 227–32
   PubMed Web of Science ®Google Scholar
• Marzullo G., Hine B. Opiate receptor function may be modulated through an oxidation‐reduction mechanism. Science 1980; 283: 227–32
   Google Scholar
• Vezina P., Stewart J. The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Res 1989; 499: 108–20
   PubMed Web of Science ®Google Scholar
• Murphy N. P., Lam H. A., Maidment N. T. A comparison of morphine‐induced locomotor and mesolimbic dopamine release in C57BL6, 129Sv and DBA2 mice. J Neurochem 2001; 79: 626–35
   PubMed Web of Science ®Google Scholar
• Woo S. H., Kim H. S. Inhibition of diazepam on morphine‐induced hyperactivity, reverse tolerance and post‐synaptic dopamine receptor supersensitivity. Pharmacol Res 2001; 44: 467–72
   PubMed Web of Science ®Google Scholar
• Del Rosario C. N., Pacchioni A. M., Cancela L. M. Influence of acute and repeated restraint stress on morphine‐induced locomotion: involvement of dopamine, opioid and glutamate receptors. Behav Brain Res 2002; 134: 229–38
   PubMed Web of Science ®Google Scholar
• Drouin C., Darracq L., Trovero F., Blanc G., Glowinski J., Cotecchia S., Tassin J. P., et al. Alpha1b‐adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 2002; 22: 2873–84
   PubMed Web of Science ®Google Scholar
• Airio J., Ahtee L. The involvement of noradrenergic transmission in the morphine‐induced locomotor hyperactivity in mice withdrawn from repeated morphine treatment. Br J Pharmacol 1999; 126: 1609–19
   PubMed Web of Science ®Google Scholar
• Handal M., Grung M., Skurtveit S., Ripel A., Morland J., et al. Pharmacokinetic differences of morphine and morphine‐glucuronides are reflected in locomotor activity. Pharmacol Biochem Behav 2002; 73: 883–92
   PubMed Web of Science ®Google Scholar